Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.
Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds
The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
Editorialists cautioned that the study does not suggest that HbA1c has limited utility in black patients, adding that there is a need to better understand the subgroups that may be vulnerable to discordant HbA1c and glucose measures.